Cancer Profiling Market Report 2025

The cancer profiling market size has grown rapidly in recent years. It will grow from $13.48 billion in 2024 to $15.05 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing cancer incidence rates, rise in precision medicine approaches, clinical adoption of biomarkers, drug development and targeted therapies, awareness, and patient advocacy.

The cancer profiling market size is expected to see rapid growth in the next few years. It will grow to $23.08 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to integration of artificial intelligence, global collaborations in research, expansion of liquid biopsy applications, regulatory support for precision medicine, increasing emphasis on early detection. Major trends in the forecast period include liquid biopsy dominance, comprehensive genomic profiling, rise of immunoprofiling, collaborative data sharing network, single-cell sequencing.

The anticipated rise in the incidence of cancer is poised to drive the growth of the cancer profiling market in the coming years. Cancer incidence, representing the number of new cancer cases within a specific population during a defined period, is on the ascent due to factors such as urbanization, an expanding aging demographic, evolving lifestyles, and various environmental and genetic influences. The surge in cancer cases underscores the importance of cancer profiling, a process that identifies specific molecular or genetic alterations in tumors, aiding in the comprehensive understanding and treatment of cancer. In 2022, the American Cancer Society projected an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the United States, highlighting the pressing need for advanced profiling techniques to address the increasing cancer burden.

The growing funding for cancer research is expected to drive the growth of the cancer profiling market in the future. Funding for cancer research refers to financial backing from various sources to support scientific investigations aimed at expanding knowledge, developing treatments, and discovering cures for different types of cancer. Cancer profiling enables targeted and personalized treatment approaches based on the molecular characteristics of cancer. For example, in 2023, the American Society for Radiation Oncology (ASTRO), a US-based organization focused on advancing radiation oncology, reported that the National Institutes of Health (NIH) received $51 billion in funding, with $9.988 billion directed to the National Cancer Institute (NCI), reflecting a $2.7 billion increase from the 2023 fiscal year. As a result, the rise in funding for cancer research is fueling the growth of the cancer profiling market.

Leading companies in the cancer profiling market are prioritizing innovation, such as expanding test coverage. These tests evaluate 517 cancer-related genes across nearly 30 solid tumor types. Broad coverage involves the comprehensive analysis of a wide range of genetic mutations, biomarkers, or molecular targets. For example, in March 2022, Illumina, Inc., a US-based biotechnology firm, introduced the TruSight Oncology Comprehensive (TSO) test, representing a significant breakthrough in cancer diagnostics. This new in vitro diagnostic test, launched in Europe, profiles cancer mutations to guide patients toward targeted therapies. It examines 517 genes from both DNA and RNA across nearly 30 solid tumor types, providing faster results within four to five days. CE-marked for European quality standards, the test reduces the need for multiple gene assays from different tissue samples.

Key players in the cancer profiling market are strategically focusing on the development of innovative in-vitro diagnostic test kits to optimize the treatment of advanced non-small cell lung cancer (NSCLC). In-vitro diagnostic test kits are specialized medical devices designed for the analysis of specimens, such as blood or tissue, outside the living organism (in vitro). One notable example is Qiagen, a leading Germany-based provider of sample and assay technologies. In May 2022, Qiagen launched the Thera screen EGFR Plus RGQ PCR Kit, an in-vitro diagnostic test specifically crafted for the sensitive analysis of EGFR mutations in non-small cell lung cancer (NSCLC) treatment. This real-time quantitative polymerase chain reaction (qPCR) test enhances detection limits, ensures faster turnaround times, and streamlines the process with automated sample extraction and results analysis. Notably, the kit now encompasses the detection of the C797S mutation, a crucial biomarker indicating resistance to third-generation EGFR tyrosine kinase inhibitors. This strategic development underscores the commitment of major industry players to advancing precision diagnostics in cancer treatment.

In January 2023, Agilent Technologies, a US-based biotechnology research company, acquired Avida Biomed Inc. for an undisclosed sum. The acquisition is intended to strengthen Agilent's expertise in molecular biology, particularly in advancing innovative tools and technologies for synthetic biology applications. Avida Biomed Inc. is also a US-based biotechnology research company.

Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation.

North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cancer profiling refers to a diagnostic procedure aimed at analyzing the genetic information within tumor cells in the body. This process provides crucial insights into specific molecular or genetic alterations present in a tumor, such as gene mutations or other changes occurring in tumor DNA.

Key technologies involved in cancer profiling encompass immunoassays, PCR (polymerase chain reaction), NGS (next-generation sequencing), microarrays, and in-situ hybridization. Immunoassays represent laboratory tests designed to measure the concentration of specific proteins or other biomolecules found in blood or urine samples. Genomic biomarkers and protein biomarkers are utilized for profiling various cancers, including breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer, and others. These profiling methods find applications in research, clinical diagnostics, screening, prognostics, and other healthcare-related purposes.

The cancer profiling market research report is one of a series of new reports that provides cancer profiling market statistics, including cancer profiling industry global market size, regional shares, competitors with a cancer profiling market share, detailed cancer profiling market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer profiling industry. This cancer profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer profiling market consists of revenues earned by entities by providing services such as surgery, chemotherapy, radiotherapy, hormonal therapy, and immunotherapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. Cancer profiling also includes sales of diagnostic tests and spectrometers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.